☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
rituximab
Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma
October 15, 2020
Innovent and Lilly's Halpryza (biosimilar- rituximab) Receive NMPA's Approval in China
October 12, 2020
Cadila to Launch its Ritucad (rituximab- biosimilar) in India
July 29, 2020
Sandoz Receives Health Canada's Approval to Launch Ziextenzo (biosimilar- pegfilgrastim) and Riximyo (biosimilar- rituximab) in Ca...
June 10, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
